FMP

FMP

Enter

ACCD - Accolade, Inc.

photo-url-https://images.financialmodelingprep.com/symbol/ACCD.png

Accolade, Inc.

ACCD

NASDAQ

Accolade, Inc., together with its subsidiaries, develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists. It also provides second opinion consultation and health care decision support services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was incorporated in 2007 and is headquartered in Plymouth Meeting, Pennsylvania.

6.89 USD

0.01 (0.145%)

Latest ACCD News

Andrew Wynn

Jan 14, 2025

Accolade, Inc. (NASDAQ:ACCD) Acquisition by Transcarent and Financial Insights

Accolade, Inc. (NASDAQ:ACCD) is a prominent player in the health advocacy and primary care sector. The company focuses on providing expert medical opinions and services to a wide range of clients. Recently, Accolade has been in the spotlight due to significant corporate developments. The company is set to be acquired by Transcarent, a move that has caused a notable surge in its stock price. On January 13, 2025, Stephen H. Barnes, Accolade's Chief Financial Officer, sold 284 shares of the compan...

Read More

Gordon Thompson

Jan 10, 2025

Accolade, Inc. (NASDAQ:ACCD) Acquisition and Financial Performance Overview

Accolade, Inc. (NASDAQ:ACCD) is a company that provides personalized health and benefits solutions. It focuses on health advocacy, expert medical opinions, and primary care services. Recently, Transcarent announced its acquisition of Accolade, a strategic move valued at approximately $621 million. This acquisition aims to create a leading platform serving over 1,400 employer and payer clients, as highlighted by the unanimous approval from both companies' Boards of Directors. On January 9, 2025,...

Read More

Reuters

Jul 17, 2024

Pernod Ricard to sell bulk of wine portfolio to Accolade Wine owners

Pernod Ricard said on Wednesday it agreed to sell the majority of its wine portfolio to the owners of Australia's Accolade Wines, disposing of a dragging division to focus on its core business of spirits.

Read More

Zacks Investment Research

Jul 12, 2024

After Plunging -46.98% in 4 Weeks, Here's Why the Trend Might Reverse for Accolade (ACCD)

Accolade (ACCD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Read More

Zacks Investment Research

Jul 11, 2024

After Plunging -47.01% in 4 Weeks, Here's Why the Trend Might Reverse for Accolade (ACCD)

Accolade (ACCD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Read More

Barrons

Jun 28, 2024

Accolade Stock Sinks After Earnings. The Case to Buy the Dip.

The tech and health company's fiscal-year earnings report weighs on shares.

Read More

Seeking Alpha

Jun 28, 2024

Accolade: Mixed Guidance (Rating Downgrade)

Accolade's full-year guidance was mixed, notwithstanding a Q1 FY 2025 results beat driven by a favorable timing factor. ACCD sees its revenue growth slowing from +14% last year to +13% in the current fiscal year, but its 3.7% FY 2025 EBITDA margin guidance was above expectations. My rating for Accolade is downgraded from a Buy to a Hold, after considering the company's outlook in light of its updated guidance.

Read More

Seeking Alpha

Jun 27, 2024

Accolade, Inc. (ACCD) Q1 2025 Earnings Call Transcript

Accolade, Inc. (NASDAQ:ACCD ) Q1 2025 Earnings Conference Call June 27, 2024 4:30 PM ET Company Participants Todd Friedman - SVP of IR Rajeev Singh - CEO Steve Barnes - CFO Conference Call Participants Richard Close - Canaccord Genuity Craig Hettenbach - Morgan Stanley Michael Cherny - Leerink Partners Jeff Garro - Stephens Inc. Ryan Daniels - William Blair Jailendra Singh - Truist Securities Jessica Tassan - Piper Sandler Ryan MacDonald - Needham & Company Stephanie Davis - Barclays Stan Berens...

Read More

Zacks Investment Research

Jun 27, 2024

Accolade (ACCD) Reports Q1 Loss, Tops Revenue Estimates

Accolade (ACCD) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.52 per share a year ago.

Read More

GlobeNewsWire

Jun 12, 2024

Accolade to Announce Fiscal First Quarter 2025 Financial Results

SEATTLE, June 12, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will release fiscal first quarter 2025 financial results on Thursday, June 27, 2024, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day.

Read More
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep